Extended Data Table 1 HER2 GOF variants in individual patients

From: Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial

  1. Amp, amplification; BOR, best overall response; cfDNA, circulating free DNA; CR, complete response; HER2, human epidermal growth factor receptor 2; GOF, gain-of-function; ISH, in situ hybridization; NE, not estimable; PR, partial response; SD, stable disease; T-DXd, trastuzumab deruxtecan; VAF, variant allele frequency. Variant types overlap with HER2 amplification. All patients are from the primary cohort T-DXd arm.
Back to article page